$0.3698
-0.0173-4.47%
In chiusura: Nov 20, 4:00 PM EST
$0.3799
0.01012.73%
Post-mercato: 6:38 PM EST

Coherus Oncology (CHRS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 9, 2026 | $-0.20 | $-0.21 | 4.76 % |
| Q2 | Aug 5, 2026 | $-0.19 | $-0.12 | -58.3 % |
| Q1 | May 11, 2026 | $-0.25 | $-0.27 | 7.41 % |
| Q4 | Mar 9, 2026 | $-0.34 | $-0.34 | 0.00 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 9, 2026 | $14.27M | $15.92M | -10.3 % |
| Q2 | Aug 5, 2026 | $14.31M | $21.61M | -33.8 % |
| Q1 | May 11, 2026 | $12.31M | $14.35M | -14.2 % |
| Q4 | Mar 9, 2026 | $12.75M | $13.70M | -6.97 % |
Coherus Oncology (CHRS) ha pubblicato l'ultima guidance il gennaio 13, 2025 per fiscal year 2024. La società ha previsto un fatturato pari a $255M - $260M per il periodo.
Rispetto alle previsioni precedenti, Coherus Oncology {{epsDirection}} ha modificato le sue previsioni di fatturato da un intervallo precedente di {{epsPriorRange}}.
Coherus Oncology ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Coherus Oncology. 4
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.21 | $-0.12 | $-0.27 | $-0.34 |
| Actual | $-0.20 | $-0.19 | $-0.25 | $-0.34 |
| Surprise | +4.76% | -58.3% | +7.41% | 0.00% |
| Revenue | ||||
| Estimate | $15.9M | $21.6M | $14.3M | $13.7M |
| Actual | $14.3M | $14.3M | $12.3M | $12.7M |
| Surprise | -10.3% | -33.8% | -14.2% | -6.97% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.20 | $-0.20 | $-0.19 | $-0.19 |
| Revenue | ||||
| Consensus | $17.1M | $18.3M | — | — |